Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Integrated Diagnostics Holdings Plc LSE:IDHC London Ordinary Share JE00BV9H9G76 ORD USD1.00
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -0.76% 3.93 3.82 3.93 3.93 3.85 3.89 61,447 16:28:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 104.5 35.6 16.0 24.1 590

Integrated Diagnostics Holdings PLC Notice of Results

19/08/2020 5:16pm

UK Regulatory (RNS & others)


Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart


From May 2020 to Nov 2020

Click Here for more Integrated Diagnostics Charts.

TIDMIDHC

RNS Number : 6298W

Integrated Diagnostics Holdings PLC

19 August 2020

Integrated Diagnostics Holdings Plc Notice of results

19 August 2020

(London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), IDHC on the London Stock Exchange, a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, will publish its unaudited results for the first half ended 30 June 2020 on Wednesday, 2 September 2020 at 7am (UK).

An analyst and investor call will be hosted at 2pm (UK) | 3pm (Egypt) on Wednesday, 2 September 2020. A live audio webcast can be accessed at this link and you may dial in using the conference call details below:

   --     Access code: 257185 
   --     UK dial in: (Toll free) 0800 640 6441 / (Int'l) +44 20 3936 2999 
   --     USA dial in: (Toll free) +1 855 9796 654 / (Int'l) +1 646 664 1960 
   --     UAE dial in: (Toll free) 800 0357 04553 

Contact

 
 IDH 
 Nancy Fahmy                    +20 (0)12 2255 7445 
  Investor Relations Director    nancy.fahmy@idhcorp.com 
 
 

About Integrated Diagnostics Holdings

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 462 branches as of 30 June 2020, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORMZGMRVLKGGZM

(END) Dow Jones Newswires

August 19, 2020 12:16 ET (16:16 GMT)

1 Year Integrated Diagnostics Chart

1 Year Integrated Diagnostics Chart

1 Month Integrated Diagnostics Chart

1 Month Integrated Diagnostics Chart
ADVFN Advertorial
Your Recent History
LSE
IDHC
Integrated..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201125 00:59:03